?s abstract) The ETS family of transcription factors play key roles in the regulation of hematopoiesis. ETS factors regulate critical events in hematopoietic development as demonstrated by the profound defects observed in mice deficient in these genes. The aberrant expression of ETS family members has been linked to the pathogenesis of several types of human and murine leukemia as well as other malignancies. MEF (myeloid elf-1 like factor) is a member of the ETS family cloned from a human megakaryocytic leukemia cell line (CMK). MEF activates transcription of genes important in hematopoiesis including the cytokines GM-CSF and IL-3. MEF interacts with the transcription factor AML1, and the AML1/ETO fusion protein, the product of the (8;21) translocation in acute myelogenous leukemia, and cooperates with AML1 in the regulation of the IL-3 promoter. To evaluate the role that MEF plays in hematopoietic cell development and function, the regulatory pathways central to MEF function will be defined. 1) A tetracycline-inducible MEF expression hematopoietic cell model will be used for differential gene expression analysis with DNA microarrays to identify target genes, which will be validated, and their regulation studied. 2) The functional domains of MEF that regulate the interaction with AML1B and cyclin A will be characterized and their role in regulating target gene expression will be studied. 3) the phenotype of MEF deficient mice generated by homologous recombination will be characterized to define the role of MEF in the development of the hematopoietic, as well as other, systems. Gross, microscopic, and cell-type specific functional abnormalities will be assessed with particular attention to the hematopoietic system. This work will contribute to defining the relationship between mechanisms of cellular development and differentiation and the establishment of disease. Work in the area of hematopathology where diagnostic skills will be developed. Experience in the analysis of mouse models, the use of emerging microarray technology to study and diagnose disease, and clinical diagnostic development will lead to an independent career as a physician scientist.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL004478-05
Application #
6872004
Study Section
Special Emphasis Panel (ZHL1-CSR-K (O1))
Program Officer
Werner, Ellen
Project Start
2001-04-05
Project End
2007-03-31
Budget Start
2005-04-01
Budget End
2007-03-31
Support Year
5
Fiscal Year
2005
Total Cost
$125,820
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yao, J J; Liu, Y; Lacorazza, H D et al. (2007) Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26:4032-7
Liu, Yan; Hedvat, Cyrus V; Mao, Shifeng et al. (2006) The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol 26:3114-23
Hedvat, Cyrus V; Teruya-Feldstein, Julie; Puig, Pere et al. (2005) Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 13:237-42
Hedvat, Cyrus V; Yao, JinJuan; Sokolic, Robert A et al. (2004) Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells. J Biol Chem 279:6395-400
Hedvat, Cyrus V; Comenzo, Raymond L; Teruya-Feldstein, Julie et al. (2003) Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 122:728-44
Hedvat, Cyrus V; Hegde, Abhijith; Chaganti, Raju S k et al. (2002) Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33:968-74